Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Communication
Treatment
Care Practice
Prevention
View all Topics
Conferences
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
EAN 2022
ESOC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Treatment
3:49
Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials
Philip Tipton
• 27 Apr 2023
1:19
Expanding research into biomarkers for RPD differentiation
Philip Tipton
• 27 Apr 2023
1:21
TREM2 as a target for disease modification in Alzheimer’s disease
Elina Svensson
• 6 Apr 2023
2:26
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Stephen Salloway
• 19 Apr 2023
2:48
TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab
Stephen Salloway
• 19 Apr 2023
1:50
Safety results of the Phase III gantenerumab GRADUATE I and II studies
Stephen Salloway
• 19 Apr 2023
4:51
Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310
Johanne Kaplan
• 30 Mar 2023
0:59
Symptomatic versus disease modifying treatments
Suzanne Hendrix
• 21 Mar 2023
4:20
Defining subgroups of patients with subjective cognitive decline more likely to progress
Giovanni Frisoni
• 30 Mar 2023
4:51
European task force recommendations: shifting memory clinics towards prevention
Giovanni Frisoni
• 30 Mar 2023
2:46
Distinguishing between disease modifying and symptomatic effects in clinical trials
Suzanne Hendrix
• 21 Mar 2023
4:23
Phase II trial of AR1001 as a potential treatment for Alzheimer’s disease
David R. Greeley
• 28 Mar 2023
2:22
Past and future of immunotherapy in Alzheimer’s disease
Mourad Tayebi
• 30 Mar 2023
9:51
Gotcha! A therapy app for proper name anomia in dementia
Alex Leff
• 3 Apr 2023
3:02
Lecanemab: drawbacks to consider
Alvaro Pascual-Leone
• 9 Jan 2023
5:24
Lecanemab: a review
Alvaro Pascual-Leone
• 9 Jan 2023
1
2
3
4
5
…
13
Next